CIK 0001678660 · Non-accelerated filer<br>Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811384762
- Phone
- (302) 467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-09 | Sandor Victor Director | Grant or award · Director Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2026-06-09 | Dorton Katina Director | Grant or award · Director Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2026-06-09 | Bonita David P Director | Grant or award · Director Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2026-06-09 | Babler Martin Director | Grant or award · Director Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2026-06-09 | FRIEDMAN PAUL A Director | Grant or award · Director Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2026-06-09 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-06-09 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2026-05-01 | Morris Charles Q Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +450,000 | $4.70 | $2.1M | 450,000 |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other disposition | −1,407,000 | 6,475,882 | ||
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other acquisition · Pre-Funded Warrants (Right to Buy) | +1,407,000 | 1,407,000 | ||
| 2026-04-21 | Bonita David P Director | Purchase | +1,689,189 | $4.44 | $7.5M | 11,808,945 |
| 2026-04-21 | Bonita David P Director | Purchase | +1,126,126 | $4.44 | $5.0M | 1,126,126 |
| 2026-04-21 | ORBIMED ADVISORS LLC Director | Purchase | +1,689,189 | $4.44 | $7.5M | 11,808,945 |
| 2026-04-21 | ORBIMED ADVISORS LLC Director | Purchase | +1,126,126 | $4.44 | $5.0M | 1,126,126 |
| 2026-04-21 | BAKER BROS. ADVISORS LP Director | Purchase · Warrants to purchase Common Stock | +114,601 | $4.44 | $509K | 1,678,273 |
| 2026-04-21 | BAKER BROS. ADVISORS LP Director | Purchase · Warrants to purchase Common Stock | +2,137,651 | $4.44 | $9.5M | 20,105,994 |
| 2026-02-04 | Combs Andrew Chief Chemistry Officer | Grant or award · Employee Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2026-02-04 | Vaddi Krishna CEO | Grant or award · Employee Stock Option (right to buy) | +837,000 | 837,000 | ||
| 2026-02-04 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2026-02-04 | Lim Bryant David CLO, CFO, Corp Sec. | Grant or award · Employee Stock Option (right to buy) | +275,000 | 275,000 |
Page 1 of 8 · 141 trades